Biodexa Pharmaceuticals (BDRX) Free Cash Flow (2013 - 2022)
Biodexa Pharmaceuticals (BDRX) reported Free Cash Flow of $38706.6 for Q4 2022, down 84.81% on a YoY basis from $254774.0 in Q4 2021, and down 5.16% sequentially from $40812.0 in Q3 2022.
Biodexa Pharmaceuticals (BDRX) Free Cash Flow (2013 - 2022) Analysis & Trends
Biodexa Pharmaceuticals (BDRX) has 8 years of Free Cash Flow data on file, last reported at $38706.6 in Q4 2022.
- For the quarter ending Q4 2022, Free Cash Flow fell 84.81% year-over-year to $38706.6; the trailing twelve-month figure through Jun 2024 stood at $38706.6 (down 51.32% YoY), and the FY2025 full-year result was -$7.4 million, up 53.14% from the prior year.
- Free Cash Flow slipped to $38706.6 in Q4 2022, from $40812.0 in the prior quarter.
- In the past five years, Free Cash Flow ranged from a high of $254774.0 in Q4 2021 to a low of -$9.2 million in Q4 2020.
- A 4-year average of -$3.9 million and a median of -$4.1 million in 2021 frame the typical range for Free Cash Flow.
- Across the five-year window, Free Cash Flow jumped 102.76% in 2021 and tumbled 84.81% in 2022, its largest moves.
- Tracing BDRX's Free Cash Flow over 4 years: stood at -$5.8 million in 2019, then sank by 58.29% to -$9.2 million in 2020, then jumped by 102.76% to $254774.0 in 2021, then tumbled by 84.81% to $38706.6 in 2022.
- Business Quant data shows BDRX's Free Cash Flow at $38706.6 in Q4 2022, $40812.0 in Q3 2022, and $254774.0 in Q4 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -19.58 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 158.09 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -1.53 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.29 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 848.30 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -354.95 Mn |
| 10 | Biodexa Pharmaceuticals | 18.43 Bn | 18.43 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2022 | 38,706.63 |
| Dec 31, 2022 | 38,706.63 |
| Sep 14, 2022 | 40,811.96 |
| Sep 14, 2022 | 40,811.96 |
| Dec 31, 2021 | 254,774.00 |
| Dec 31, 2021 | 254,774.00 |
| Sep 17, 2021 | -4.06 Mn |
| Sep 17, 2021 | -4.06 Mn |
| Dec 31, 2020 | -9.24 Mn |
| Dec 31, 2020 | -9.24 Mn |
| Sep 10, 2020 | -8.81 Mn |
| Sep 10, 2020 | -8.81 Mn |
| Dec 31, 2019 | -5.84 Mn |
| Dec 31, 2019 | -5.84 Mn |
| Dec 31, 2016 | -14.59 Mn |
| Dec 31, 2016 | -14.59 Mn |
| Dec 31, 2015 | -17.45 Mn |
| Dec 31, 2015 | -17.45 Mn |
| Dec 31, 2014 | -7.01 Mn |
| Dec 31, 2014 | -7.01 Mn |